Amrutanjan Health Care Q2 Profit Hits Rs 17.28 Crore

Revenue grew to Rs 135.18 crore from Rs 117.70 crore YoY; interim dividend of Rs 1 declared.

Reader Takeaway: Strong OTC segment performance drives revenue growth, though beverage segment losses and ESOP restructuring remain key focus areas.

What just happened

Amrutanjan Health Care has released its unaudited standalone financial results for the quarter ended September 30, 2026. The company posted a net profit of Rs 17.28 crore, up from Rs 13.96 crore in the same period last year. Total revenue for the quarter reached Rs 135.18 crore. Alongside these earnings, the board has approved an interim dividend of Rs 1 per equity share for FY 2026-27.

Why this matters

The steady growth in the OTC products segment, which generated Rs 90.94 crore in revenue and Rs 23.29 crore in segment results, remains the primary profit engine for the company. The declaration of an interim dividend signals management's confidence in cash flows and commitment to returning value to shareholders.

Business and Governance Update

Management confirmed the withdrawal of the "ESOP 2 Scheme" due to unmet vesting conditions, replacing it with the "Second Phase ESOP 2 Scheme" approved earlier this year. Additionally, the company has fully resolved its legacy lease rent dispute with the Tamil Nadu government, with property attachments withdrawn following the payment of Rs 202.75 lakh earlier this year.

Segment Performance

The company’s performance remains split across key verticals:

• OTC Products: Revenue Rs 90.94 crore (Rs 23.29 crore profit)
• Women’s Hygiene & Personal Care: Revenue Rs 40.48 crore (Rs 0.46 crore profit)
• Beverages: Revenue Rs 3.03 crore (Loss of Rs 2.41 crore)

What to track next

Investors should monitor the scaling of the Women’s Hygiene & Personal Care segment to see if it can contribute more significantly to the bottom line, and observe whether the beverage business can move toward profitability in upcoming quarters.